Kura Oncology, Inc(KURA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KURA Kura Oncology, Inc

交易中 08-18 15:51:23 EDT

12.31

+1.03

+9.13%

最高12.85	最低11.99	成交量346.63万
今开11.99	昨收11.28	日振幅7.62%
总市值10.93亿	流通市值8.69亿	总股本8,877万
成交额4,311万	换手率4.91%	流通股本7,060万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KURA","market":"US","secType":"STK","nameCN":"Kura Oncology, Inc","latestPrice":12.31,"timestamp":1787082682133,"preClose":11.28,"halted":0,"volume":3466337,"delay":0,"changeRate":0.09131205673758876,"floatShares":70602200,"shares":88774365,"eps":-3.36681,"marketStatus":"交易中","change":1.03,"latestTime":"08-18 15:51:23 EDT","open":11.985,"high":12.845,"low":11.985,"amount":43112348.058268994,"amplitude":0.076241,"askPrice":12.32,"askSize":129,"bidPrice":12.3,"bidSize":322,"shortable":3,"etf":0,"ttmEps":-3.36681,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787083200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1446699600000,"exchange":"NASDAQ","adjPreClose":11.28,"preHourTrading":{"tag":"盘前","latestPrice":12.01,"preClose":11.28,"latestTime":"09:29 EDT","volume":49683,"amount":595660.864407,"timestamp":1787059799983,"change":0.73,"changeRate":0.064716,"amplitude":0.032801},"postHourTrading":{"tag":"盘后","latestPrice":12.1,"preClose":11.28,"latestTime":"19:59 EDT","volume":102804,"amount":1207888.9162,"timestamp":1787011172273,"change":0.82,"changeRate":0.072695,"amplitude":0.109043},"volumeRatio":1.686559,"impliedVol":0.6414,"impliedVolPercentile":0.3586},"requestUrl":"/m/hq/s/KURA","defaultTab":"news","newsList":[{"id":"1166882660","title":"Kura Oncology在KCRS 2026大会公布：Darlifarnib联合卡博替尼对初治透明细胞肾癌患者展现持久临床活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1166882660","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166882660?lang=zh_cn&edition=full","pubTime":"2026-07-27 18:33","pubTimestamp":1785148390,"startTime":"0","endTime":"0","summary":"Kura Oncology公布了其Darlifarnib联合卡博替尼方案，在未接受过卡博替尼治疗的透明细胞肾细胞癌患者中，展现出持久的临床活性。该研究结果于2026年KCRS大会上正式披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KURA","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116209259","title":"Kura Oncology与Kyowa Kirin公布Ziftomenib联合7+3方案治疗初诊AML的积极长期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1116209259","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116209259?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:06","pubTimestamp":1781179579,"startTime":"0","endTime":"0","summary":"Kura Oncology与Kyowa Kirin近日公布了其联合研发的Ziftomenib与标准7+3化疗方案相结合，用于治疗新确诊的急性髓系白血病（AML）患者的长期随访结果。数据显示，该联合疗法展现出令人鼓舞的持久疗效与安全性特征，为这一难治性血液肿瘤患者带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169343050","title":"科拉肿瘤学报告Darlifarnib联合Adagrasib在KRAS G12C突变实体瘤中展现强劲临床活性与安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=1169343050","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169343050?lang=zh_cn&edition=full","pubTime":"2026-05-26 18:03","pubTimestamp":1779789794,"startTime":"0","endTime":"0","summary":"科拉肿瘤学（Kura Oncology）公布的最新数据显示，其药物Darlifarnib与Adagrasib的联合疗法，在治疗携带KRAS G12C突变的实体瘤患者中，表现出强劲的临床活性和良好的安全性特征。这一积极结果进一步验证了该联合疗法的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175538737","title":"Kura Oncology治疗周期达56周 数据截止时三分之一患者仍在接受治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1175538737","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175538737?lang=zh_cn&edition=full","pubTime":"2026-04-17 18:05","pubTimestamp":1776420302,"startTime":"0","endTime":"0","summary":"Kura Oncology, Inc公布的最新数据显示，患者在接受该公司治疗方案后，治疗持续时间已成功达到56周。值得注意的是，在数据截止时间点，仍有约三分之一的研究参与者继续维持治疗状态。\n这一数据反映了该治疗方案在临床实践中的持续性和患者耐受性表现。56周的治疗周期为评估长期疗效和安全性提供了重要参考依据，而相当比例患者选择继续治疗也暗示了该方案可能具备良好的临床获益潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151151548","title":"Kura Oncology公布达利法尼联合卡博替尼在既往接受卡博替尼治疗的透明细胞肾细胞癌患者中展现强劲活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1151151548","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151151548?lang=zh_cn&edition=full","pubTime":"2026-04-17 18:00","pubTimestamp":1776420018,"startTime":"0","endTime":"0","summary":"Kura Oncology, Inc 宣布，其药物达利法尼联合卡博替尼在既往接受过卡博替尼治疗的透明细胞肾细胞癌患者群体中，显示出令人鼓舞的治疗活性。该组合疗法在此类难治性患者中观察到了显著的治疗效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517162278","title":"瑞银：维持Kura Oncology(KURA.US)评级，由买入调整至买入评级, 目标价由27.00美元调整至14.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517162278","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517162278?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:05","pubTimestamp":1741277144,"startTime":"0","endTime":"0","summary":"瑞银：维持Kura Oncology(KURA.US)评级，由买入调整至买入评级, 目标价由27.00美元调整至14.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/07000548577058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516169663","title":"Kura Oncology, Inc.盘中异动 下午盘急速跳水5.06%报7.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516169663","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516169663?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:27","pubTimestamp":1741033650,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时27分，Kura Oncology, Inc.股票出现波动，股价快速跳水5.06%。截至发稿，该股报7.32美元/股，成交量75.0327万股，换手率0.93%，振幅7.33%。Kura Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于发现和开发用于治疗实体肿瘤和血癌的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304042731989a5f18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304042731989a5f18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","KURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516548051","title":"Kura Oncology, Inc.2024财年实现净利润-1.74亿美元，同比减少13.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516548051","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516548051?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:01","pubTimestamp":1740931271,"startTime":"0","endTime":"0","summary":"3月3日，Kura Oncology, Inc.公布财报，公告显示公司2024财年净利润为-1.74亿美元，同比减少13.73%；其中营业收入为53.88百万美元，每股基本收益为-2.02美元。从资产负债表来看，Kura Oncology, Inc.总负债6.27亿美元，其中短期债务4.49百万美元，资产负债比为1.67，流动比率为0.10。机构评级：截至2025年3月3日，当前有12家机构对Kura Oncology, Inc.目标价做出预测，其中目标均价为27.75美元，其中最低目标价为10.00美元，最高目标价为40.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000150abe4acd2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000150abe4acd2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110051286","title":"异动解读 | Kura Oncology财报超预期,盘后股价大涨6.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110051286","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110051286?lang=zh_cn&edition=full","pubTime":"2025-02-27 05:53","pubTimestamp":1740606783,"startTime":"0","endTime":"0","summary":"Kura Oncology公司(KURA)在2025年2月26日星期三的盘后交易中股价大涨6.69%,引起市场广泛关注。\n\n公司发布的最新财报数据显示,其第四季度GAAP每股亏损为0.22美元,优于分析师一致预期的0.65美元亏损,超出预期幅度高达66.15%;同时,公司季度销售额达到5388万美元,远高于市场预期的850万美元,增长幅度超过533.92%。\n\n财报数据明显超出市场预期,反映出公司业绩和发展势头良好,投资者对此反应积极,推动了公司股价在盘后市场的大涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132024829","title":"Kura Oncology第四季度GAAP每股亏损$(0.22)优于预期$(0.65)，销售额达$53.88M远超预期$8.50M","url":"https://stock-news.laohu8.com/highlight/detail?id=1132024829","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132024829?lang=zh_cn&edition=full","pubTime":"2025-02-27 05:36","pubTimestamp":1740605792,"startTime":"0","endTime":"0","summary":"Kura Oncology报告称，其季度每股亏损$，优于分析师一致预期的$，超出预期66.15%。相比去年同期每股亏损$，同比改善60%。公司报告季度销售额为$53.88M，远超分析师预期的$8.50M，增长533.92%。以上内容来自Benzinga Earnings专栏，原文如下：Kura Oncology  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 66.15 percent. This is a 60 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $53.88 million which beat the analyst consensus estimate of $8.50 million by 533.92 percent.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Kura Oncology第四季度GAAP每股亏损$(0.22)优于预期$(0.65)，销售额达$53.88M远超预期$8.50M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510332698","title":"Kura Oncology, Inc.盘中异动 股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510332698","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510332698?lang=zh_cn&edition=full","pubTime":"2025-02-12 00:49","pubTimestamp":1739292574,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日00时49分，Kura Oncology, Inc.股票出现异动，股价快速下挫5.01%。Kura Oncology, Inc.股票所在的生物技术行业中，整体跌幅为1.45%。其相关个股中，Omega Therapeutics, Inc.、Lipella Pharmaceuticals Inc.、Oramed Pharmaceuticals Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2984.89%、1321.42%、435.90%，振幅较大的相关个股有Omega Therapeutics, Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.，振幅分别为143.33%、59.46%、58.60%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于发现和开发用于治疗实体肿瘤和血癌的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502120049359881d4b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502120049359881d4b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KURA","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509272661","title":"Kura Oncology, Inc.盘中异动 股价大跌12.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509272661","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509272661?lang=zh_cn&edition=full","pubTime":"2025-02-06 22:32","pubTimestamp":1738852335,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日22时32分，Kura Oncology, Inc.股票出现波动，股价急速跳水12.04%。Kura Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。其相关个股中，Lipella Pharmaceuticals Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Immatics N V C/Wts 01/07/2025 涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为3890.21%、340.23%、114.95%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Rani Therapeutics Holdings, Inc.、Relmada Therapeutics, Inc.，振幅分别为33.33%、15.97%、14.26%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于发现和开发用于治疗实体肿瘤和血癌的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223215abc4d4a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223215abc4d4a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509170464","title":"Kura Oncology, Inc.盘中异动 股价大涨5.09%报8.67美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509170464","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509170464?lang=zh_cn&edition=full","pubTime":"2025-02-05 00:52","pubTimestamp":1738687969,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日00时52分，Kura Oncology, Inc.股票出现波动，股价快速上涨5.09%。截至发稿，该股报8.67美元/股，成交量92.6882万股，换手率1.19%，振幅7.52%。Kura Oncology, Inc.股票所在的生物技术行业中，整体涨幅为1.34%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于发现和开发用于治疗实体肿瘤和血癌的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205005250abc242f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205005250abc242f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508124353","title":"Kura Oncology, Inc.盘中异动 下午盘股价大涨5.06%报8.31美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508124353","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508124353?lang=zh_cn&edition=full","pubTime":"2025-02-04 02:44","pubTimestamp":1738608290,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日02时44分，Kura Oncology, Inc.股票出现波动，股价急速拉升5.06%。Kura Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.38%。其相关个股中，Hcw Biologics Inc.、Invivyd, Inc.、Gh Research Plc涨幅较大，Hcw Biologics Inc.、Cyclerion Therapeutics, Inc.、Briacell Therapeutics Corp.较为活跃，换手率分别为717.48%、662.83%、467.97%，振幅较大的相关个股有Hcw Biologics Inc.、Invivyd, Inc.、Briacell Therapeutics Corp.，振幅分别为170.13%、151.80%、63.94%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于发现和开发用于治疗实体肿瘤和血癌的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204024450abc13978&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204024450abc13978&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KURA","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507767539","title":"Kura Oncology, Inc.盘中异动 股价大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507767539","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507767539?lang=zh_cn&edition=full","pubTime":"2025-01-31 00:57","pubTimestamp":1738256260,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日00时57分，Kura Oncology, Inc.股票出现异动，股价快速上涨5.07%。Kura Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.15%。其相关个股中，Tectonic Therapeutic, Inc.、Alterity Therapeutics Limited、Kazia Therapeutics Limited涨幅较大，Kazia Therapeutics Limited、Silexion Therapeutics Corp、Alterity Therapeutics Limited较为活跃，换手率分别为1676.96%、250.03%、221.87%，振幅较大的相关个股有Cero Therapeutics Holdings, Inc.、Alterity Therapeutics Limited、Coeptis Therapeutics Holdings Inc C/Wts 28/10/2027 ，振幅分别为65.98%、61.86%、56.73%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于发现和开发用于治疗实体肿瘤和血癌的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131005741a2346e07&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131005741a2346e07&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505708704","title":"Kura Oncology, Inc.盘中异动 下午盘股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505708704","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505708704?lang=zh_cn&edition=full","pubTime":"2025-01-23 04:18","pubTimestamp":1737577118,"startTime":"0","endTime":"0","summary":"北京时间2025年01月23日04时18分，Kura Oncology, Inc.股票出现异动，股价急速拉升5.01%。Kura Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.40%。其相关个股中，Revolution Medicines Inc C/Wts 17/12/2026 、Eterna Therapeutics Inc.、Immunoprecise Antibodies Ltd.涨幅较大，Immunoprecise Antibodies Ltd.、Hepion Pharmaceuticals, Inc.、Tonix Pharmaceuticals Holding Corp.较为活跃，换手率分别为1030.17%、464.21%、96.98%，振幅较大的相关个股有Revolution Medicines Inc C/Wts 17/12/2026 、Immunoprecise Antibodies Ltd.、Immatics N V C/Wts 01/07/2025 ，振幅分别为68.99%、60.53%、53.51%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于发现和开发用于治疗实体肿瘤和血癌的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123041838a22bf969&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123041838a22bf969&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KURA","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503425706","title":"Kura Oncology, Inc.盘中异动 股价大涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503425706","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503425706?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:32","pubTimestamp":1736951537,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时32分，Kura Oncology, Inc.股票出现异动，股价急速上涨5.10%。Kura Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.77%。其相关个股中，Monte Rosa Therapeutics, Inc.、Exicure, Inc.、Generation Bio Co.涨幅较大，Windtree Therapeutics, Inc.、Phio Pharmaceuticals Corp.、Oncolytics Biotech Inc.较为活跃，换手率分别为185.06%、52.88%、35.43%，振幅较大的相关个股有Onconetix, Inc.、Klotho Neurosciences, Inc.、Vincerx Pharma, Inc.，振幅分别为14.29%、12.00%、10.72%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于发现和开发用于治疗实体肿瘤和血癌的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223218a222fe16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223218a222fe16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502607048","title":"Kura Oncology, Inc.盘中异动 快速下跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502607048","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2502607048?lang=zh_cn&edition=full","pubTime":"2025-01-10 23:00","pubTimestamp":1736521241,"startTime":"0","endTime":"0","summary":"北京时间2025年01月10日23时00分，Kura Oncology, Inc.股票出现异动，股价急速跳水5.01%。Kura Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.83%。其相关个股中，Conduit Pharmaceuticals Inc.、Precision Biosciences, Inc.、Moolec Science Sa C/Wts 涨幅较大，Zyversa Therapeutics, Inc.、Conduit Pharmaceuticals Inc.、Precision Biosciences, Inc.较为活跃，换手率分别为1084.50%、276.27%、188.88%，振幅较大的相关个股有Conduit Pharmaceuticals Inc.、Precision Biosciences, Inc.、Zyversa Therapeutics, Inc.，振幅分别为64.51%、41.78%、37.29%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于发现和开发用于治疗实体肿瘤和血癌的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501102300419861f010&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501102300419861f010&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502170455","title":"Kura Oncology, Inc.盘中异动 股价大跌5.14%报7.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2502170455","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2502170455?lang=zh_cn&edition=full","pubTime":"2025-01-09 03:03","pubTimestamp":1736363021,"startTime":"0","endTime":"0","summary":"北京时间2025年01月09日03时03分，Kura Oncology, Inc.股票出现异动，股价急速跳水5.14%。Kura Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.38%。其相关个股中，Sana Biotechnology, Inc.、Silo Pharma, Inc.、Vir Biotechnology, Inc.涨幅较大，Silo Pharma, Inc.、Nls Pharmaceutics Ltd.、60 Degrees Pharmaceuticals, Inc.较为活跃，换手率分别为3548.25%、612.79%、598.69%，振幅较大的相关个股有Sana Biotechnology, Inc.、Silo Pharma, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为192.73%、153.20%、89.00%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于发现和开发用于治疗实体肿瘤和血癌的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250109030342985fa375&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250109030342985fa375&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KURA","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2501727729","title":"Scotiabank：维持Kura Oncology(KURA.US)评级，由与大盘持平调整至与大盘持平评级, 目标价由18.00美元调整至10.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2501727729","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2501727729?lang=zh_cn&edition=full","pubTime":"2025-01-08 21:52","pubTimestamp":1736344334,"startTime":"0","endTime":"0","summary":"Scotiabank：维持Kura Oncology(KURA.US)评级，由与大盘持平调整至与大盘持平评级, 目标价由18.00美元调整至10.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/08215247277179.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["KURA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kuraoncology.com","stockEarnings":[{"period":"1week","weight":0.1452},{"period":"1month","weight":0.0387},{"period":"3month","weight":0.2589},{"period":"6month","weight":0.3286},{"period":"1year","weight":0.5368},{"period":"ytd","weight":0.0857}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0395},{"period":"3month","weight":0.0531},{"period":"6month","weight":0.1259},{"period":"1year","weight":0.2008},{"period":"ytd","weight":0.1331}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kura Oncology, Inc.最初于2007年11月在特拉华州注册成立。他们是一家临床阶段的生物制药公司，致力于实现精准药物治疗癌症的前景。他们的产品线由针对癌症信号通路的小分子候选产品组成，在这些信号通路中，有很强的科学和临床理由来改善结果，他们打算将其与分子或细胞诊断相结合，以确定最有可能对治疗做出反应的患者。他们正在对三种候选产品进行临床试验：齐夫托米尼、替比法尼和KO-2806。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.002309},{"month":2,"riseRate":0.545455,"avgChangeRate":0.031825},{"month":3,"riseRate":0.545455,"avgChangeRate":-0.033425},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.021049},{"month":5,"riseRate":0.545455,"avgChangeRate":0.027851},{"month":6,"riseRate":0.545455,"avgChangeRate":0.041051},{"month":7,"riseRate":0.454545,"avgChangeRate":0.017727},{"month":8,"riseRate":0.545455,"avgChangeRate":0.083521},{"month":9,"riseRate":0.5,"avgChangeRate":0.12103},{"month":10,"riseRate":0.3,"avgChangeRate":-0.077132},{"month":11,"riseRate":0.8,"avgChangeRate":0.052179},{"month":12,"riseRate":0.454545,"avgChangeRate":0.00367}],"exchange":"NASDAQ","name":"Kura Oncology, Inc","nameEN":"Kura Oncology"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kura Oncology, Inc(KURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kura Oncology, Inc(KURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kura Oncology, Inc,KURA,Kura Oncology, Inc股票,Kura Oncology, Inc股票老虎,Kura Oncology, Inc股票老虎国际,Kura Oncology, Inc行情,Kura Oncology, Inc股票行情,Kura Oncology, Inc股价,Kura Oncology, Inc股市,Kura Oncology, Inc股票价格,Kura Oncology, Inc股票交易,Kura Oncology, Inc股票购买,Kura Oncology, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kura Oncology, Inc(KURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kura Oncology, Inc(KURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}